Sunshine Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SBFM Nasdaq 2836 sunshinebiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sunshine Biopharma, Inc.

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM) - Oct 28th, 2025 12:10 pm
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea - Oct 28th, 2025 5:45 am
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline - Oct 20th, 2025 5:45 am
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin - Oct 16th, 2025 5:45 am
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM) - Oct 14th, 2025 8:45 am
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM) - Oct 14th, 2025 6:50 am
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience - Oct 14th, 2025 5:00 am
Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections - Oct 9th, 2025 6:00 am
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market - Jul 2nd, 2025 6:00 am
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market - Jun 11th, 2025 6:30 am
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year - May 15th, 2025 2:15 pm
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market - May 6th, 2025 6:30 am
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion - Apr 21st, 2025 6:30 am
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - Apr 3rd, 2025 8:50 am
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules - Apr 2nd, 2025 11:20 am
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer - Apr 2nd, 2025 6:00 am
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year - Apr 1st, 2025 3:09 pm
Sunshine Biopharma signs agreement for rights to market two generic antibiotics - Mar 25th, 2025 7:06 am
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada - Mar 24th, 2025 6:00 am
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market - Mar 10th, 2025 7:00 am